Injectable Thyroid Drug Market Analysis Based on Hypothyroidism, Hyperthyroidism, and Thyroid Cancer, 2024 to 2034

<p>The global <strong>injectable thyroid drug market</strong> is set to surge at a CAGR of 5.7% by 2034. The industry is projected to increase from US$ 439.65 million in 2024 to US$ 765.4 million by 2034. In 2023, the market was valued at US$ 414.4 million.</p><table> <tbody> <tr> <th scope='row'>Attributes</th> <td>Details</td> </tr> <tr> <th scope='row'>Base Value, 2023</th> <td>US$ 414.4 million</td> </tr> <tr> <th scope='row'>Injectable Thyroid Drug Market Size, 2024</th> <td>US$ 439.65 million</td> </tr> <tr> <th scope='row'>Projected Revenue, 2034</th> <td>US$ 765.4 million</td> </tr> <tr> <th scope='row'>Value-based CAGR (2024 to 2034)</th> <td>5.7%</td> </tr> </tbody></table><p>Country-wise Insights</p><table> <tbody> <tr> <th scope='row'>Countries</th> <td>Value CAGR (2024 to 2034)</td> </tr> <tr> <th scope='row'>United States</th> <td>4.2%</td> </tr> <tr> <th scope='row'>Germany</th> <td>3.8%</td> </tr> <tr> <th scope='row'>Canada</th> <td>5.6%</td> </tr> <tr> <th scope='row'>United Kingdom</th> <td>3.0%</td> </tr> <tr> <th scope='row'>France</th> <td>5.3%</td> </tr> </tbody></table><p>Category-wise Insights</p><table> <tbody> <tr> <th scope='row'>Molecules</th> <td>Value CAGR (2024 to 2034)</td> </tr> <tr> <th scope='row'>Levothyroxine Sodium</th> <td>5.1%</td> </tr> <tr> <th scope='row'>Liothyronine Sodium</th> <td>5.4%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>Sales Channel</th> <td>Value CAGR (2024 to 2034)</td> </tr> <tr> <th scope='row'>Hospitals</th> <td>5.1%</td> </tr> <tr> <th scope='row'>Specialty Clinics</th> <td>5.2%</td> </tr> <tr> <th scope='row'>Retail Pharmacies</th> <td>5.5%</td> </tr> </tbody></table>

<p>全球注射用甲状腺药物市场预计到2034年将以5.7%的复合年增长率激增。该行业预计将从2024年的4.3965亿美元增长至2034年的7.654亿美元。截至2023年，市场规模已达4.144亿美元。</p><table> <tbody> <tr> <th scope='row'>属性</th> <td>详细信息</td> </tr> <tr> <th scope='row'>2023年基础价值</th> <td>4.144亿美元</td> </tr> <tr> <th scope='row'>2024年注射用甲状腺药物市场规模</th> <td>4.3965亿美元</td> </tr> <tr> <th scope='row'>2034年预计收入</th> <td>7.654亿美元</td> </tr> <tr> <th scope='row'>基于价值的复合年增长率（2024年至2034年）</th> <td>5.7%</td> </tr> </tbody></table><p>按国家划分的洞察</p><table> <tbody> <tr> <th scope='row'>国家</th> <td>基于价值的复合年增长率（2024至2034年）</td> </tr> <tr> <th scope='row'>美国</th> <td>4.2%</td> </tr> <tr> <th scope='row'>德国</th> <td>3.8%</td> </tr> <tr> <th scope='row'>加拿大</th> <td>5.6%</td> </tr> <tr> <th scope='row'>英国</th> <td>3.0%</td> </tr> <tr> <th scope='row'>法国</th> <td>5.3%</td> </tr> </tbody></table><p>按类别划分的洞察</p><table> <tbody> <tr> <th scope='row'>分子</th> <td>基于价值的复合年增长率（2024至2034年）</td> </tr> <tr> <th scope='row'>左甲状腺素钠</th> <td>5.1%</td> </tr> <tr> <th scope='row'>三碘甲状腺原氨酸钠</th> <td>5.4%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>销售渠道</th> <td>基于价值的复合年增长率（2024至2034年）</td> </tr> <tr> <th scope='row'>医院</th> <td>5.1%</td> </tr> <tr> <th scope='row'>专科诊所</th> <td>5.2%</td> </tr> <tr> <th scope='row'>零售药店</th> <td>5.5%</td> </tr> </tbody></table>